Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Yahoo! Finance
This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 20.59%. A quarter ago, it was expected that this company would post a loss of $0.34 per share when it actually produced a loss of $0.24, delivering a surprise of 29.41%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Tango Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $11.61 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 44.35%. This compares to year-ago revenues of $10.73 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Tango The
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at B. Riley from $16.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.MarketBeat
- Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at Guggenheim from $18.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business HighlightsBusiness Wire
TNGX
Earnings
- 8/7/24 - Beat
TNGX
Sec Filings
- 11/20/24 - Form SC
- 11/18/24 - Form 4
- 11/8/24 - Form 4
- TNGX's page on the SEC website